Last reviewed · How we verify
NCT00339664
Analyses of Human Samples Collected in Clinical Trials
trial in Leukemia, Myeloid in 2,579 participants. Completed in 26 March 2020.
17 March 2020
Quick facts
| Lead sponsor | National Cancer Institute (NCI) |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 2,579 |
| Start date | 2 July 2003 |
| Primary completion | 17 March 2020 |
| Estimated completion | 26 March 2020 |
| Sites | 17 locations across Netherlands, United States |
Conditions studied
- Leukemia, Myeloid — all drugs for Leukemia, Myeloid →
- Neoplasm Metastasis — all drugs for Neoplasm Metastasis →
- Leukemia, Lymphoid — all drugs for Leukemia, Lymphoid →
- Prostate Cancer — all drugs for Prostate Cancer →
Sponsor
National Cancer Institute (NCI)
Who can join
Under 100, any sex, with Leukemia, Myeloid or Neoplasm Metastasis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Cancer patients in clinical trials donate various human samples (e.g., serum, plasma, blood, urine, feces, bile, saliva) for research purposes. The purpose of this study is to conduct further analyses on these existing samples from clinical trials that are being performed outside of, but in collaboration with, the National Cancer Institute.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT00339664
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Leukemia, Myeloid
Currently open trials in the same condition.
- NCT06643962 — Venetoclax Combined with Intensive Therapy for Acute Myeloid Leukemia Patients with Lower Early Peripheral Blast Clearan · NA · recruiting
- NCT06537726 — Breath Analysis for the Detection of Invasive Fungal Infections · recruiting
- NCT06152809 — CIML NK Cells With Venetoclax for AML · Phase 1 · recruiting
- NCT06138587 — Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation · Phase 1 · recruiting
- NCT05805605 — Allo HSCT Using RIC and PTCy for Hematological Diseases · Phase 2 · recruiting
Other National Cancer Institute (NCI) trials
Trials by the same sponsor.
- NCT07147231 — Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cem · Phase 1, PHASE2 · recruiting
- NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
- NCT07281417 — Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasa · Phase 2 · recruiting
- NCT07012044 — A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After · Phase 1 · not yet recruiting
- NCT07437950 — Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A Myel · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00339664 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Cancer Institute (NCI)
- Last refreshed: 30 March 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00339664.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing